TWEAK/Fn14 signalling driven super-enhancer reprogramming promotes pro-metastatic metabolic rewiring in triple-negative breast cancer.
Nicholas SimJean-Michel CarterKamalakshi DekaBenita Kiat Tee TanYirong SimSuet-Mien TanYinghui LiPublished in: Nature communications (2024)
Triple Negative Breast Cancer (TNBC) is the most aggressive breast cancer subtype suffering from limited targeted treatment options. Following recent reports correlating Fibroblast growth factor-inducible 14 (Fn14) receptor overexpression in Estrogen Receptor (ER)-negative breast cancers with metastatic events, we show that Fn14 is specifically overexpressed in TNBC patients and associated with poor survival. We demonstrate that constitutive Fn14 signalling rewires the transcriptomic and epigenomic landscape of TNBC, leading to enhanced tumour growth and metastasis. We further illustrate that such mechanisms activate TNBC-specific super enhancers (SE) to drive the transcriptional activation of cancer dependency genes via chromatin looping. In particular, we uncover the SE-driven upregulation of Nicotinamide phosphoribosyltransferase (NAMPT), which promotes NAD+ and ATP metabolic reprogramming critical for filopodia formation and metastasis. Collectively, our study details the complex mechanistic link between TWEAK/Fn14 signalling and TNBC metastasis, which reveals several vulnerabilities which could be pursued for the targeted treatment of TNBC patients.
Keyphrases
- end stage renal disease
- estrogen receptor
- ejection fraction
- transcription factor
- chronic kidney disease
- newly diagnosed
- small cell lung cancer
- gene expression
- prognostic factors
- peritoneal dialysis
- cancer therapy
- dna damage
- genome wide
- signaling pathway
- poor prognosis
- oxidative stress
- dna methylation
- young adults
- rna seq
- papillary thyroid
- anti inflammatory
- breast cancer cells
- heat shock
- replacement therapy